🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06848621
Starting soon Not applicable

A Single-blind, Randomized, Controlled Clinical Study of Flash Stimulation Therapy in Parkinson's Disease

NCT06848621 · tracked via the Priya Life Science China tracker
Sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase
Not applicable
Started
2025-03-01
Last updated
2025-02-27

Condition(s) studied

Parkinson's Disease

Investigational drug(s) / intervention(s)

40Hz light modulation glasses100Hz light modulation glasses

40Hz light modulation glasses: A one-week flash stimulation therapy (JK-PMEG2700K light modulation glasses \[light source\]) using flash stimulation between 20:00 and 21:00.

100Hz light modulation glasses: A one-week flash stimulation therapy (JK-PMEG2700K light modulation glasses \[light source\]) using flash stimulation between 20:00 and 21:00.

Study summary

The aim of this study was to evaluate the effect of flash stimulation therapy on the function of the cerebral glymphatic system and efficacy of improving symptoms in PD patients.

Eligibility

Sex
ALL
Min age
50 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: 1. PD patients who meet the diagnostic criteria of the International Movement Disorders Association (MDS), between the ages of 50 and 70 years, the course of disease ≤5 years, and the Hoehn \& Yahr stage ≤3; 2. Anti-PD drugs were taken regularly for at least one month before screening, and symptoms were stable; 3. The fixed bedtime in the past month is between 9:00 p.m. and 1:00 a.m., and the total sleep time is ≥6 hours; 4. Have the ability to understand and voluntarily sign informed consent; 5. Have good compliance and are willing to complete all follow-up required by this program. Exclusion Criteria: 1. Secondary insomnia: including sleep disorders (restless leg syndrome, periodic limb movement disorder, sleep-related breathing disorders, etc.), physical diseases, mental disorders, psychoactive substance abuse; 2. suffering from photosensitive dermatitis, epilepsy and other diseases that are not suitable for flash stimulation; 3. Alcohol, coffee, or drug abusers in the past 6 months; 4. Mental illness: such as anxiety, depression, schizophrenia and post-traumatic stress disorder caused by insomnia; 5. Used drugs or health products that regulate sleep function or affect sleep within 14 days before enrollment or less than 5 drug half-lives; 6. Taking drugs that may impair cognitive ability, such as anticholinergic drugs, memory enhancing drugs, etc., within 7 days before enrollment; 7. the subject is unable to complete the test or follow-up; 8. suffering from other neurodegenerative diseases; 9. There are endoplants in the body that cannot be examined by MRI; 10. Inability to lie flat; 11. Other situations in which the researcher considers it inappropriate to participate in the study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang

More Second Affiliated Hospital, Zhejiang University, School of Medicine trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06848621 on ClinicalTrials.gov ↗ ← All trials in China